ArticleWorld journal of oncology2026
Clinical Relevance of Prostate-Specific Membrane Antigen-Lipid Rafts Association and Membrane Protein Interactions in Prostatic Adenocarcinoma.
Article in World journal of oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lipid rafts or detergent-resistant membranes (DRMs) have played a fundamental role during prostate-specific membrane antigen (PSMA) activation by serving as platforms for internalization and cell signaling. In the current study, we aimed to evaluate the clinical significance of PSMA-lipid rafts association in prostate adenocarcinoma. Methods: The study was carried out on two normal prostate (NP), 11 benign prostate hyperplastic (BPH), and 10 prostate cancer (PC) samples. Immunohistochemical analysis for PSMA, CD34, and Ki67 was performed. Serum levels of prostate-specific antigen (PSA) were assayed by Immulite autoanalyzer. DRMs were isolated from LNCaP cells, NP, BPH, and PC tissues. Using Triton X-100, PSMA, dipeptidyl peptidase IV (DPPIV), binding immunoglobulin protein (BiP), and Flotillin-2 were analyzed in both soluble and insoluble fractions by Western blot analysis. Results: The findings demonstrate that PSMA is overexpressed in PC compared to normal and benign prostate tissues. The strongest staining of PSMA was membranous, with apical accentuation in neoplastic cells. Furthermore, upregulation of PSMA was concomitant with high expression of CD34 and Ki67 in malignant prostate. Our data indicate that PSMA, DPPIV, and BiP are distributed in the insoluble and soluble fractions of the analyzed PC samples. Nevertheless, the level of these membrane proteins is higher in the soluble fraction as compared to the DRMs in prostate adenocarcinoma. Conclusion: Overall, this preliminary study provides initial insights into the potential clinical relevance of the association between PSMA and lipid rafts in human prostatic adenocarcinoma. The observed co-distribution of PSMA with DPPIV and BiP in the DRM fractions of PC samples suggests a possible association among these membrane proteins that may contribute to PC progression. Although these findings are preliminary, they support the hypothesis that crosstalk between these proteins could occur. Further studies are required to elucidate the underlying molecular mechanisms and to determine whether targeting PSMA and its associated membrane partners may represent a promising therapeutic strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.